SAB Biotherapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving SAB Biotherapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes
The story matters when it changes SAB Biotherapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.SAB Biotherapeutics, Inc. (SABS) Q1 2026 Earnings Call Transcript
Investors are testing whether SAB Biotherapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest SABS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
SAB Biotherapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →